Corneal angiogenesis and lymphangiogenesis

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 5, 2012, Pages 548-554

  Regenfu, Birgit ^a   Bock, Felix ^a   Cursiefen, Claus ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

angiogenesis; corneal lymphangiogenesis; genetic heterogeneity; inhibitors of lymphangiogenesis

Indexed keywords

AGANIRSEN; ANGIOSTATIN; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE SODIUM PHOSPHATE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FLUOROMETHOLONE; INSULIN RECEPTOR SUBSTRATE 1; PLATELET DERIVED GROWTH FACTOR BB; PREDNISOLONE ACETATE; THROMBOSPONDIN 1; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTING CELL; ANTISENSE THERAPY; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CHROMOSOME 13; CHROMOSOME 15; CHROMOSOME 18; CHROMOSOME 4; CORNEA; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; CORNEA TRANSPLANTATION; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; GENETIC HETEROGENEITY; GRAFT SURVIVAL; HUMAN; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; RISK FACTOR; SURVIVAL;

ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GENETIC HETEROGENEITY; HUMANS; LYMPHANGIOGENESIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 84865960769     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328357b4a2     Document Type: Review

References (64)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
2. Augustin HG. Angiogenesis in the female reproductive system. Exs 2005:35-52.
3. Gerhardt H, Betsholtz C. How do endothelial cells orientate? Exs 2005:3-15.
4. Caduff JH, Fischer LC, Burri PH. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anat Rec 1986; 216:154-164.
5. Patan S, Alvarez MJ, Schittny JC, Burri PH. Intussusceptive microvascular growth: a common alternative to capillary sprouting. Arch Histol Cytol 1992; 55 (Suppl):65-75.
6. Djonov V, Makanya AN. New insights into intussusceptive angiogenesis. Exs 2005:17-33.
7. Kilarski WW, Gerwins P. A new mechanism of blood vessel growth: hope for new treatment strategies. Discov Med 2009; 8:23-27.
8. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005; 115:2363-2372.
9. Nakao S, Noda K, Zandi S, et al. VAP-1-mediated M2 macrophage infiltration underlies IL-1beta- but not VEGF-A-induced lymph- and angiogenesis. Am J Pathol 2011; 178:1913-1921.
10. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006; 103:11405-11410.
11. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443:993-997.
12. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45:2666-2673.
13. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor A neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008; 126:71-77.
14. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010; 184:535-539.
15. Hajrasouliha AR, Funaki T, Sadrai Z, et al. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest Ophthalmol Vis Sci 2012; 53:1244-1250.
16. Wu FT, Stefanini MO, Mac Gabhann F, et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010; 14:528-552.
17. Owen LA, Uehara H, Cahoon J, et al. Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PloS One 2012; 7:e33576.
18. Cho YK, Uehara H, Young JR, et al. Vascular endothelial growth factor receptor 1 morpholino decreases angiogenesis in a murine corneal suture model. Invest Ophthalmol Vis Sci 2012; 53:685-692.
19. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48:2545-2552.
20. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011; 52:8718-8723.
21. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:1375-1382.
22. Papathanassiou M, Theodoropoulou S, Analitis A, et al. Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a metaanalysis. Cornea 2012. [Epub ahead of print]
23. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50:2095-2102.
24. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 2010; 51:4569-4573.
25. Yu CQ, Zhang M, Matis KI, et al. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 2008; 49:3870-3878.
26. Stevenson W, Cheng SF, Dastjerdi MH, et al. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 2012; 10:67-83.
27. Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. ArchOphthalmol 2011; 129:445-452.
28. Steele MM, Kelley PM, Schieler AM, Tempero RM. Glucocorticoids suppress corneal lymphangiogenesis. Cornea 2011; 30:1442-1447.
29. Al-Mahmood S, Colin S, Farhat N, et al. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther 2009; 329:496-504.
30. Cloutier F, Lawrence M, Goody R, et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 2012; 53:1195-1203.
31. Cursiefen C, Bock F, Horn FK, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009; 116:1630-1637.
32. Hos D, Regenfuss B, Bock F, et al. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 2011; 52:5778-5785.
33. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15:1023-1030.
34. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45:1117-1124.
35. Cursiefen C, Maruyama K, Bock F, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med 2011; 208:1083-1092.
36. Heishi T, Hosaka T, Suzuki Y, et al. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol 2010; 176:1950-1958.
37. Rohan RM, Fernandez A, Udagawa T, et al. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000; 14:871-876.
38. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J 2003; 17:2112-2114.
39. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J 2004; 18:1050-1059.
40. Nakao S, Maruyama K, Zandi S, et al. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J 2010; 24:504-513.
41. Regenfuss B, Onderka J, Bock F, et al. Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol 2010; 177:501-510.
42. Maruyama K, Nakazawa T, Cursiefen C, et al. The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages. Invest Ophthalmol Vis Sci 2012; 53:3145-3153.
43. Yamada J, Streilein JW. Fate of orthotopic corneal allografts in C57BL/6 mice. Trans Immunol 1998; 6:161-168.
44. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011; 52:4694-4702.
45. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol: Official J Am Soc Clin Oncol 2008; 26:4672-4678.
46. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for antiangiogenic therapy. Pharmacogenomics 2007; 8:49-66.
47. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333:679-685.
48. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Prac Oncol 2004; 1:39-43.
49. Longo R, D'Andrea M, Sarmiento R,Gasparini G. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab. Exp Opin Invest Drugs 2010; 19 (Suppl 1):S41-S50.
50. Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60:1245-1249.
51. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006; 15:2955-2961.
52. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49:3611-3616.
53. Rogers MS, D'Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res 2006; 312:561-574.
54. Ward EG, Grosios K, Markham AF, Jones PF. Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2. Cytogenet Cell Genet 2001; 94:147-154.
55. Carlson CB, Liu Y, Keck JL, Mosher DF. Influences of the N700S thrombospondin-1 polymorphism on protein structure and stability. J Bio Chem 2008; 283:20069-20076.
56. Stenina OI, Desai SY, Krukovets I, et al. Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation 2003; 108:1514-1519.
57. Galan A, Ferlin A, Caretti L, et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 2010; 117:1769-1774.
58. Al-Kateb H, Mirea L, Xie X, et al. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes 2007; 56:2161-2168.
59. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51:1635-1639.
60. Nakao S, Zandi S, Hata Y, et al. Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis. Blood 2011; 117:1081-1090.
61. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 2004; 101:11658-11663.
62. Hajrasouliha AR, Sadrai Z, Chauhan SK, Dana R. b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea 2012; 31:804-809.
63. Yuen D, Leu R, Sadovnikova A, Chen L. Increased lymphangiogenesis and hemangiogenesis in infant cornea. Lymph Res Biol 2011; 9:109-114.
64. Ecoiffier T, Yuen D, Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci 2010; 51:2436-2440.